RJR-2429
RJR-2429 is a drug that acts as an agonist at neural nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. RJR-2429 is stronger than nicotine but weaker than epibatidine in most assays, and with high affinity for both α3β4 and α4β2 subtypes, as well as the less studied α1βγδ subtype.[1][2][3]
 | |
| Identifiers | |
|---|---|
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H16N2 |
| Molar mass | 188.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- Bencherif M, Schmitt JD, Bhatti BS, Crooks P, Caldwell WS, Lovette ME, Fowler K, Reeves L, Lippiello PM (March 1998). "The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors". The Journal of Pharmacology and Experimental Therapeutics. 284 (3): 886–94. PMID 9495846.CS1 maint: multiple names: authors list (link)
- Yokotani K, Okada S, Nakamura K (June 2002). "Characterization of functional nicotinic acetylcholine receptors involved in catecholamine release from the isolated rat adrenal gland". European Journal of Pharmacology. 446 (1–3): 83–7. doi:10.1016/s0014-2999(02)01819-8. PMID 12098588.CS1 maint: multiple names: authors list (link)
- Bhatti BS, Strachan JP, Breining SR, Miller CH, Tahiri P, Crooks PA, Deo N, Day CS, Caldwell WS (May 2008). "Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands". The Journal of Organic Chemistry. 73 (9): 3497–507. doi:10.1021/jo800028q. PMID 18363376.CS1 maint: multiple names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.